Results 91 to 100 of about 53,892 (275)

Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]

, 2012
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone, Rajalingam, Krishnaraj, Dikic, Ivan   +2 more
core   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, Volume 78, Issue 1, Page 12-25, January 2026.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial

Haematologica, 2018
Mantle cell lymphoma patients have variable clinical courses, ranging from indolent cases that do not require immediate treatment to aggressive, rapidly progressing diseases.
Riccardo Bomben, Simone Ferrero, Tiziana D’Agaro, Michele Dal Bo, Alessandro Re, Andrea Evangelista, Angelo Michele Carella, Alberto Zamò, Umberto Vitolo, Paola Omedè, Chiara Rusconi, Luca Arcaini, Luigi Rigacci, Stefano Luminari, Andrea Piccin, Delong Liu, Adrian Wiestner, Gianluca Gaidano, Sergio Cortelazzo, Marco Ladetto, Valter Gattei   +20 more
doaj   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

Risk of Type II Diabetes Mellitus Among B‐Cell Non‐Hodgkin's Lymphoma Survivors

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Purpose Advancing therapies have increased B‐cell Non‐Hodgkin's Lymphoma (B‐NHL) patient survival. However, data are limited on the risk of type II diabetes mellitus (type II DM) in adult survivors following treatment. This study examines the risk of type II DM among a Utah population of B‐NHL survivors, compared to the general population ...
Ellenor Chi, Derek K. Chang, Chun‐Pin Esther Chang, Seungmin Kim, Jihye Park, John Snyder, Vikrant Deshmukh, Michael G. Newman, Catherine J. Lee, Mia Hashibe   +9 more
wiley   +1 more source

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

Exploring the Role of Long Noncoding RNAs in Breast Cancer Progression: A Comprehensive Study on Biomarkers and Therapeutic Approaches

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Background Among the many forms of cancer that plague women all over the globe, breast cancer (BC) is one of the most prevalent kinds. BC is a multifaceted disease that can manifest in many ways depending on the individual. Aims The identification of new biomarkers that may be used to diagnose and prognosis of the BC, as well as those that can
Ramin Moeini, Amin AhsanAlkhat, Saeid Ghorbian   +2 more
wiley   +1 more source

Spontaneous Splenic Rupture and Rituximab-Induced Acute Thrombocytopenia in a Patient with High-Risk Mantle Cell Lymphoma

Case Reports in Hematology, 2019
Mantle cell lymphoma is a relatively rare type of mature B-cell non-Hodgkin’s lymphoma with an incidence of approximately 8 cases per million persons per year.
Jared Williams, Shingi Chiruka
doaj   +1 more source

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling [PDF]

, 1983
BACKGROUND: Mantle cell lymphoma (MCL) is currently an incurable entity, and new therapeutic approaches are needed. We have applied a high-throughput phospho-proteomic technique to MCL cell lines to identify activated pathways and we have then validated ...
Chiara Pighi, Ting-Lei Gu, Irene Dalai, Stefano Barbi, Claudia Parolini, Anna Bertolaso, Serena Pedron, Alice Parisi, Jianmin Ren, Daniela Cecconi, Marco Chilosi, Fabio Menestrina, Alberto Zamò   +12 more
core   +1 more source

Practical implications of the World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Categories and ancillary testing for subtyping of hematolymphoid tumors on FNA biopsy cytopathology using a pattern‐based approach

Cancer Cytopathology, Volume 134, Issue 1, January 2026.
Abstract The objective of the recently published World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology (WHO system) is to standardize the diagnostic approach to fine‐needle aspiration biopsies of hematolymphoid tissues.
Mats Ehinger, Maria Calaminici, Immacolata Cozzolino, Pio Zeppa, Andrew S. Field   +4 more
wiley   +1 more source